Ipratropium bromide/Albuterol sulfate

异丙托溴铵/硫酸沙丁胺醇

Report date: 2022/01/14 13:23:58

Base Information

Drug NameIpratropium bromide/Albuterol sulfate
Drug Alias NameAlbuterol sulfate/Ipratropium bromide硫酸沙丁胺醇/异丙托溴铵Ipratropium Bromide/SalbutamolIpratropium bromide and Albuterol sulfateIpratropium bromide/Salbutamol sulfate +[6] 
ClassificationSmall molecules
Mechanisms of ActionBeta-2 adrenergic receptor agonistsMuscarinic acetylcholine receptor antagonists
TargetsMuscarinic acetylcholine receptorBeta-2 adrenergic receptor
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveBronchial SpasmAsthma
Global Approved IndicationsPulmonary Disease, Chronic ObstructiveBronchial SpasmAsthma
Approved Indications in ChinaBronchial SpasmAsthma
Original Approved Country/TerritoryFrance
Original Approved Date1995/01/01
Country/TerritoryUnited StatesFranceMainland China
CombinationsYes Ipratropium bromideSalbutamol sulfate
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgTaiwan Biotech Co LtdBeijing Sintong Biotech Co Ltd +[4] 
Inactive CompaniesPharmobedient Consulting LLC
Active IndicationsPulmonary Disease, Chronic ObstructiveBronchial SpasmAsthma
Inactive IndicationsN/A

Other Information

ATC CodeR03AL02
Related LinksKEGG